Have a personal or library account? Click to login
Effects of naringin and valproate interaction on liver steatosis and dyslipidaemia parameters in male C57BL6 mice Cover

Effects of naringin and valproate interaction on liver steatosis and dyslipidaemia parameters in male C57BL6 mice

Open Access
|Apr 2022

References

  1. Singh D, Gupta S, Verma I, Morsy MA, Nair AB, Ahmed AF. Hidden pharmacological activities of valproic acid: A new insight. Biomed Pharmacother 2021;142:112021. doi: 10.1016/j.biopha.2021.112021
  2. Pitt B, Sutton NR, Wang Z, Goonewardena SN, Holinstat M. Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19. Eur J Pharmacol 2021;898:173988. doi: 10.1016/j.ejphar.2021.173988
  3. Đikić D, Jutrić D, Dominko K. The dual nature of the antiepileptic drug valproic acid, with possible beneficial effects in Alzheimer’s disease. SEEMEDJ 2017;1:74–89. doi: 10.26332/seemedj.v1i1.26
  4. NCBI. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet] [displayed 31 July 2020]. Available at https://www.ncbi.nlm.nih.gov/books/NBK548284/
  5. Chaudhary S, Ganjoo P, Raiusddin S, Parvez S. Nephroprotective activities of quercetin with potential relevance to oxidative stress induced by valproic acid. Protoplasma 2015;252:209–17. doi: 10.1007/s00709-014-0670-8
  6. Celik E, Tunali S, Gezginci-Oktayoglu S, Bolkent S, Can A, Yanardag R. Vitamin U prevents valproic acid-induced liver injury through supporting enzymatic antioxidant system and increasing hepatocyte proliferation triggered by inflammation and apoptosis. Toxicol Mech Methods 2021;31:600–8. doi: 10.1080/15376516.2021.1943089
  7. Salimi A, Alyan N, Akbari N, Jamali Z, Pourahmad J. Selenium and L-carnitine protects from valproic acid-Induced oxidative stress and mitochondrial damages in rat cortical neurons. Drug Chem Toxicol 2020;1–8. [Online ahead of print] doi: 10.1080/01480545.2020.1810259
  8. Shirani K, Yousefsani BS, Shirani M, Karimi G. Protective effects of naringin against drugs and chemical toxins induced hepatotoxicity: A review. Phytother Res 2020;34:1734–44. doi: 10.1002/ptr.6641
  9. Koroglu OF, Gunata M, Vardi N, Yildiz A, Ates B, Colak C, Tanriverdi LH, Parlakpinar H. Protective effects of naringin on valproic acid-induced hepatotoxicity in rats. Tissue Cell 2021;72:101526. doi: 10.1016/j.tice.2021.101526
  10. Zhang X, Zhang Y, Gao W, Guo Z, Wang K, Liu S, Duan Z, Chen Y. Naringin improves lipid metabolism in a tissue-engineered liver model of NAFLD and the underlying mechanisms. Life Sci 2021;277:119487. doi: 10.1016/j.lfs.2021.119487
  11. Syed AA, Reza MI, Shafiq M, Kumariya S, Singh P, Husain A, Hanif K, Gayen JR. Naringin ameliorates type 2 diabetes mellitus-induced steatohepatitis by inhibiting RAGE/NF-κB mediated mitochondrial apoptosis. Life Sci 2020;257:118118. doi: 10.1016/j.lfs.2020.118118
  12. Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington (DC): National Academies Press; 2011.
  13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502. doi: 10.1093/clinchem/18.6.499
  14. Oršolić N, Landeka Jurčević I, Đikić D, Rogić D, Odeh D, Balta V, Perak Junaković E, Terzić S, Jutrić D. Effect of propolis on diet-induced hyperlipidemia and atherogenic indices in mice. Antioxidants (Basel) 201;8:156. doi: 10.3390/antiox8060156
  15. Đikić D, Landeka I, Knežević F, Mojsović-Ćuić A, Benković V, Horvat-Knežević A, Lončar G, Teparić R, Rogić D. Carbendazim impends hepatic necrosis when combined with imazalil or cypermethrin. Basic C l in Ph a rm a co l To x i co l 2 0 1 2 ; 1 1 0 : 4 3 3 – 4 0 . do i : 10.1111/j.1742-7843.2011.00831.x
  16. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–75. doi: 10.1016/S0021-9258(19)52451-6
  17. Landeka Jurčević I, Dora M, Guberović I, Petras M, Rimac S, Brnčić, Đikić D. Polyphenols from wine lees as a novel functional bioactive compound in the protection against oxidative stress and hyperlipidaemia. Food Technol Biotechnol 2017;55:109–16. doi: 10.17113/ftb.55.01.17.4894
  18. Nagababu E, Rifkind JM, Boindala S, Nakka L. Assessment of antioxidant activity of eugenol in vitro and in vivo. Methods Mol Biol 2010;610:165–80. doi: 10.1007/978-1-60327-029-8_10
  19. Mu H, Zhou Q, Yang R, Zeng J, Li X, Zhang R, Tang W, Li H, Wang S, Shen T, Huang X, Dou L, Dong J. Naringin attenuates high fat diet induced non-alcoholic fatty liver disease and gut bacterial dysbiosis in mice. Front Microbiol 2020;11:585066. doi: 10.3389/fmicb.2020.585066
  20. Bellringer ME, Rahman K, Coleman R. Sodium valproate inhibits the movement of secretory vesicles in rat hepatocytes. Biochem J 1988;249:513–9. doi: 10.1042/bj2490513
  21. Grünig D, Szabo L, Marbet M, Krähenbühl S. Valproic acid affects fatty acid and triglyceride metabolism in HepaRG cells exposed to fatty acids by different mechanisms. Biochem Pharmacol 2020;177:113860. doi: 10.1016/j.bcp.2020.113860
  22. Lee MH, Hong I, Kim M, Lee BH, Kim JH, Kang KS, Kim HL, Yoon BI, Chung H, Kong G, Lee MO. Gene expression profiles of murine fatty liver induced by the administration of valproic acid. Toxicol Appl Pharmacol 2007;220:45–59. doi: 10.1016/j.taap.2006.12.016
  23. Ma L, Wang Y, Chen X, Zhao L, Guo Y. Involvement of CYP2E1-ROS-CD36/DGAT2 axis in the pathogenesis of VPA-induced hepatic steatosis in vivo and in vitro. Toxicology 2020;445:152585. doi: 10.1016/j.tox.2020.152585
  24. Bai X, Hong W, Cai P, Chen Y, Xu C, Cao D, Yu W, Zhao Z, Huang M, Jin J. Valproate induced hepatic steatosis by enhanced fatty acid uptake and triglyceride synthesis. Toxicol Appl Pharmacol 2017;324:12–25. doi: 10.1016/j.taap.2017.03.022
  25. Aires CCP, Ijlst L, Stet F, Prip-Buus C, de Almeida IT, Duran M, Wanders RJ, Silva MF. Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis. Biochem Pharmacol 2010;79:792–9. doi: 10.1016/j.bcp.2009.10.011
  26. Kim HJ, Oh GT, Park YB, Lee MK, Seo HJ, Choi MS. Naringin alters the cholesterol biosynthesis and antioxidant enzyme activities in LDL receptor-knockout mice under cholesterol fed condition. Life Sci 2004;74:1621–34. doi: 10.1016/j.lfs.2003.08.026
  27. Liang H, Ward WF. PGC-1alpha: a key regulator of energy metabolism. Adv Physiol Educ 2006;30:145–51. doi: 10.1152/advan.00052.2006
  28. van Raalte DH, Li M, Pritchard PH, Wasan KM. Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm Res 2004;21:1531–8. doi: 10.1023/b:pham.0000041444.06122.8d
  29. Tahri-Joutey M, Andreoletti P, Surapureddi S, Nasser B, Cherkaoui-Malki M, Latruffe N. Mechanisms mediating the regulation of peroxisomal fatty acid beta-oxidation by PPARα. Int J Mol Sci 2021;22:8969. doi: 10.3390/ijms22168969
  30. Lira VA, Benton CR, Yan Z, Bonen A. PGC-1alpha regulation by exercise training and its influences on muscle function and insulin sensitivity. Am J Physiol Endocrinol Metab 2010;299:E145–61. doi: 10.1152/ajpendo.00755.2009
  31. Vluggens A, Andreoletti P, Viswakarma N, Jia Y, Matsumoto K, Kulik W, Khan M, Huang J, Guo D, Yu S, Sarkar J, Singh I, Rao MS, Wanders RJ, Reddy JK, Cherkaoui-Malki M. Reversal of mouse Acyl-CoA oxidase 1 (ACOX1) null phenotype by human ACOX1b isoform. Lab Invest 2010;90:696–708. doi: 10.1038/labinvest.2010.46
  32. Reddy JK, Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu Rev Nutr 2001;21:193–230. doi: 10.1146/annurev.nutr.21.1.193
  33. Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, Gonzalez FJ. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem 1998;273:5678–84. doi: 10.1074/jbc.273.10.5678
  34. Vamecq J, Vallee L, Fontaine M, Lambert D, Poupaert J, Nuyts JP. CoA esters of valproic acid and related metabolites are oxidized in peroxisomes through a pathway distinct from peroxisomal fatty and bile acyl-CoA beta-oxidation. FEBS Lett 1993;322:95–100. doi: 10.1016/0014-5793(93)81545-b
  35. Ponchaut S, Draye JP, Veitch K, Van Hoof F. Influence of chronic administration of valproate on ultrastructure and enzyme content of peroxisomes in rat liver and kidney. Oxidation of valproate by liver peroxisomes. Biochem Pharmacol 1991;41:1419–28. doi: 10.1016/0006-2952(91)90557-L
  36. Van den Branden C, Roels F. Peroxisomal beta-oxidation and sodium valproate. Biochem Pharmacol 1985;34:2147–9. doi: 10.1016/00062952(85)90409-5
  37. Wang Y, Nakajima T, Gonzalez FJ, Tanaka N. PPARs as metabolic regulators in the liver: lessons from liver-specific PPAR-null mice. Int J Mol Sci 2020;21:2061. doi: 10.3390/ijms21062061
  38. McMullen PD, Bhattacharya S, Woods CG, Sun B, Yarborough K, Ross SM, Miller ME, McBride MT, LeCluyse EL, Clewell RA, Andersen ME. A map of the PPARα transcription regulatory network for primary human hepatocytes. Chem Biol Interact 2014;209:14–24. doi: 10.1016/j.cbi.2013.11.006
  39. Varanasi U, Chu R, Huang Q, Castellon R, Yeldandi AV, Reddy JK. Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene. J Biol Chem 1996;271:2147–55. doi: 10.1074/jbc.271.4.2147
  40. Yaacob NS, Norazmi MN, Gibson GG, Kass GE. The transcription of the peroxisome proliferator-activated receptor alpha gene is regulated by protein kinase C. Toxicol Lett 2001;125:133–41. doi: 10.1016/s0378-4274(01)00433-7
  41. Ke JY, Kliewer KL, Hamad EM, Cole RM, Powell KA, Andridge RR, Straka SR, Yee LD, Belury MA. The flavonoid, naringenin, decreases adipose tissue mass and attenuates ovariectomy-associated metabolic disturbances in mice. Nutr Metab (Lond) 2015;12:1. doi: 10.1186/17437075-12-1
  42. Dayarathne LA, Ranaweera SS, Natraj P, Rajan P, Lee YJ, Han CH. Restoration of the adipogenic gene expression by naringenin and naringin in 3T3-L1 adipocytes. J Vet Sci 2021;22:e55. doi: 10.4142/jvs.2021.22.e55
  43. Zeng J, Deng S, Wang Y, Li P, Tang L, Pang Y. Specific inhibition of acyl-CoA oxidase-1 by an acetylenic acid improves hepatic lipid and reactive oxygen species (ROS) metabolism in rats fed a high fat diet. J Biol Chem 2017;292:3800–9. doi: 10.1074/jbc.M116.763532
  44. Komulainen T, Lodge T, Hinttala R, Bolszak M, Pietilä M, Koivunen P, Hakkola J, Poulton J, Morten KJ, Uusimaa J. Sodium valproate induces mitochondrial respiration dysfunction in HepG2 in vitro cell model. Toxicology 2015;331:47–56. doi: 10.1016/j.tox.2015.03.001
  45. Pourahmad J, Eskandari MR, Kaghazi A, Shaki F, Shahraki J, Fard JK. A new approach on valproic acid induced hepatotoxicity: involvement of lysosomal membrane leakiness and cellular proteolysis. Toxicol In Vitro 2012;26:545–51. doi: 10.1016/j.tiv.2012.01.020
  46. Jafarian I, Eskandari MR, Mashayekhi V, Ahadpour M, Hosseini MJ. Toxicity of valproic acid in isolated rat liver mitochondria. Toxicol Mech Methods 2013;23:617–23. doi: 10.3109/15376516.2013.821567
  47. Jung UJ, Kim HJ, Lee JS, Lee MK, Kim HO, Park EJ, Kim HK, Jeong TS, Choi MS. Naringin supplementation lowers plasma lipids and enhances erythrocyte antioxidant enzyme activities in hypercholesterolemic subjects. Clin Nutr 2003;22:561–8. doi: 10.1016/s0261-5614(03)00059-1
  48. Demonty I, Lin Y, Zebregs YE, Vermeer MA, van der Knaap HC, Jäkel M, Trautwein EA. The citrus flavonoids hesperidin and naringin do not affect serum cholesterol in moderately hypercholesterolemic men and women. J Nutr 2010;140:1615–20. doi: 10.3945/jn.110.124735
  49. Raffoul-Orozco AK, Ávila-González AE, Rodríguez-Razón CM, García-Cobian TA, Pérez-Guerrero EE, García-Iglesias T, Rubio-Arellano ED. Combination effect naringin and pravastatin in lipid profile and glucose in obese rats. Life Sci 2018;193:87–92. doi: 10.1016/j.lfs.2017.11.044
DOI: https://doi.org/10.2478/aiht-2022-73-3608 | Journal eISSN: 1848-6312 | Journal ISSN: 0004-1254
Language: English, Croatian, Slovenian
Page range: 71 - 82
Submitted on: Oct 1, 2021
|
Accepted on: Feb 1, 2022
|
Published on: Apr 7, 2022
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2022 David Jutrić, Domagoj Đikić, Almoš Boroš, Dyna Odeh, Sandra Domjanić Drozdek, Romana Gračan, Petar Dragičević, Irena Crnić, Irena Landeka Jurčević, published by Institute for Medical Research and Occupational Health
This work is licensed under the Creative Commons Attribution 4.0 License.